• Clovis should put itself up for sale, activist Armistice says fiercepharma
    December 20, 2018
    Even before GlaxoSmithKline laid out an eye-popping $5.1 billion to buy PARP drugmaker Tesaro earlier this month, analysts were speculating that PARP rival Clovis Oncology would be a prime acquisition target. One of the company’s largest investors apparen
PharmaSources Customer Service